Trial Profile
The Efficacy of Bendamustine, Gemcytabine, Dexamethasone (BGD) Salvage Chemotherapy With Autologous Stem Cell Transplantation (ASCT) Consolidation in Advanced Classical Hodgkin Lymphoma Patients Not Responding to ABVD Therapy- Multicentre Phase II Clinical Study (PLRG-HL1/BURGUND)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 16 Apr 2024
Price :
$35
*
At a glance
- Drugs Bendamustine (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Gemcitabine (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- Acronyms BURGUND
- 11 Apr 2024 Planned End Date changed from 30 Sep 2023 to 30 Sep 2024.
- 11 Apr 2024 Planned primary completion date changed from 30 Sep 2023 to 30 Jun 2024.
- 31 Mar 2023 Status changed from recruiting to active, no longer recruiting.